Company Summary - IS Pharma PLC (LSE:ISPH)
66.50p
0.50p
(-0.75%)
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £20.451m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Development and commercial exploitation of healthcare products and related activities
| Financials - Interim (5/11/2008) | ||
|---|---|---|
| Turnover | £m | 5.81 |
| Pre-tax Profit | £m | 1.48 |
| EPS | p | 6.50 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Geoff McMillan | Chairman |
| Tim Wright | Chief Executive |
| Nigel Goldsmith | Finance Director & Company Sec |
Products Brands & Subsidiaries
Products & Brands
Acoranil©; Aloxi; AquiHex; AquiHex© 2%; ContiSol; Cryogesic; Dermogesic; Dermogesic©; Haemopressin; Isoplex; Isoplex©...
Subsidiaries
Acorus Therapeutics Ltd; Is Pharmaceuticals Ltd
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| Interim Results | 05/11/2008 |
| Statement re launch of ISOPLEX® ... | 03/11/2008 |
| Notice of Results | 14/10/2008 |